Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

Abstract Background Acquired resistance to BRAF inhibitors (BRAFi) is a near-universal phenomenon caused by numerous genetic and non-genetic alterations. In this study, we evaluated the spectrum, onset, pattern of progression, and subsequent clinical outcomes associated with specific mechanisms of r...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2015-12, Vol.51 (18), p.2792-2799
Hauptverfasser:	Johnson, Douglas B, Menzies, Alexander M, Zimmer, Lisa, Eroglu, Zeynep, Ye, Fei, Zhao, Shilin, Rizos, Helen, Sucker, Antje, Scolyer, Richard A, Gutzmer, Ralf, Gogas, Helen, Kefford, Richard F, Thompson, John F, Becker, Jürgen C, Berking, Carola, Egberts, Friederike, Loquai, Carmen, Goldinger, Simone M, Pupo, Gulietta M, Hugo, Willy, Kong, Xiangju, Garraway, Levi A, Sosman, Jeffrey A, Ribas, Antoni, Lo, Roger S, Long, Georgina V, Schadendorf, Dirk
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired Antineoplastic Agents - therapeutic use Australia Biomarkers, Tumor - antagonists & inhibitors Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism BRAF Dabrafenib Disease Progression Disease-Free Survival DNA Mutational Analysis Drug Resistance, Neoplasm - genetics Europe Female Genetic Predisposition to Disease Hematology, Oncology and Palliative Medicine Humans Kaplan-Meier Estimate Male MAPK MEK1 Melanoma - drug therapy Melanoma - enzymology Melanoma - genetics Melanoma - mortality Melanoma - pathology Meta-analysis Middle Aged Mutation NRAS Phenotype Proportional Hazards Models Protein Kinase Inhibitors - therapeutic use Proto-Oncogene Proteins B-raf - antagonists & inhibitors Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins B-raf - metabolism Resistance Risk Factors Signal Transduction - drug effects Skin Neoplasms - drug therapy Skin Neoplasms - enzymology Skin Neoplasms - genetics Skin Neoplasms - mortality Skin Neoplasms - pathology Splice Time Factors Treatment Outcome United States Vemurafenib
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!